Conditions/Pancreatic Cancer/Chapter
Pancreatic Cancer Treatment
Resectability category, chemotherapy sequencing, biliary drainage, and supportive care shape a multimodal plan — not a single package.
Treatment follows stage, tumour location, vessel relationships, and overall fitness. Surgery is central for appropriately selected resectable disease; chemotherapy is part of most pathways. Borderline tumours often receive neoadjuvant therapy before any attempt at resection. Supportive care — enzymes, nutrition, pain control, and glucose management — is not optional add-on care; it sustains the whole plan.
Figure labels (English)
- Resectability
- Systemic therapy
- Support
Related educational figures
Tap a figure to enlarge.
Head tumours: Whipple Body/tail: distal resection
Who may be a candidate?
- Patients with staging that defines resectable, borderline, or locally advanced disease
- Candidates for neoadjuvant therapy before reconsideration of surgery
- People needing jaundice management, enzymes, nutrition, and pain control alongside oncology
Possible advantages
- Resectability framing prevents both hasty futile operations and premature nihilism
- Neoadjuvant sequences can test biology and improve R0 odds in borderline cases
- Supportive care protects energy, digestion, and quality of life during treatment
Limits & realistic expectations
- Locally advanced arterial encasement usually precludes upfront curative resection
- Metastatic disease prioritises systemic therapy over classic curative surgery
- Not every jaundiced patient needs a routine preoperative stent
Step-by-step overview
- 1
Confirm resectability class
Pancreas-protocol imaging places disease as resectable, borderline, or locally advanced — plus metastatic status.
- 2
Multidisciplinary plan
Surgery, medical oncology, gastroenterology, and radiology agree on sequencing and drainage needs.
- 3
Treat systemic risk
Neoadjuvant or adjuvant chemotherapy (and selected radiotherapy) follows evidence and board review.
- 4
Support the patient
Enzymes, nutrition, pain control, and glucose management run in parallel with cancer therapy.
- 5
Reassess after therapy
Borderline cases are restaged; conversion to resection is considered only when R0 odds and fitness align.
Key points
- Surgical candidacy in three framesTap for details
Resectable disease without distant spread opens a resection conversation. Borderline vessel contact often leads to neoadjuvant therapy first. Locally advanced major arterial involvement usually means primary surgery is not appropriate — systemic therapy and selected conversion strategies come first.
- Resectable → surgery discussed early
- Borderline → neoadjuvant then restage
- Locally advanced → primary resection usually unsuitable
- Chemotherapy and radiotherapyTap for details
Systemic therapy before and/or after surgery is common. Selected cases add radiotherapy. In advanced disease, chemotherapy plus molecularly guided options focuses on control and quality of life.
- Supportive care is core treatmentTap for details
Enzyme replacement, nutrition support, pain control, and glucose management protect energy and dignity through the pathway — they are not optional extras.
- Neoadjuvant approach in borderline diseaseTap for details
Limited relationships with the portal vein, superior mesenteric vein, or arteries often lead to systemic therapy first. After restaging, experienced centres may discuss resection — including selected vascular resection — when R0 odds are realistic.
- When biliary stents helpTap for details · key note inside
Not every jaundiced patient needs routine preoperative stenting. Cholangitis, markedly elevated bilirubin, delayed surgery, or neoadjuvant plans are typical reasons for ERCP drainage; timing is joint.
- ImportantTap for details · key note inside
Educational information only — not a substitute for clinical evaluation or personalised advice. Treatment sequencing is individualised after resectability imaging, fitness assessment, and tumour-board discussion.
Frequently asked questions
- Does ‘cannot operate’ as a first phrase settle everything?Tap for details
No. Resectability and conversion potential are clarified after quality imaging and multidisciplinary review — not after a single casual comment.
- When is neoadjuvant chemotherapy used?Tap for details
Often in borderline vessel relationships, and increasingly in selected resectable pathways per centre protocol, to shrink disease and test biology before major surgery.
- Do I always need a bile-duct stent before surgery?Tap for details
No. Stenting is considered for cholangitis, very high bilirubin, planned neoadjuvant delay, or other clinical needs — timing is shared by surgery and gastroenterology.
- What supportive treatments matter most?Tap for details
Pancreatic enzyme replacement, nutrition support, pain control, and blood-sugar management often matter as much as the ‘main’ drugs for day-to-day function.
- Can I get a second opinion?Tap for details
Yes. Bring complete imaging discs and pathology; high-volume pancreatic boards frequently refine resectability and sequencing.
More chapters in this hub
Appointment / info
Educational information only; not a substitute for clinical evaluation.
Medical editor: Assoc. Prof. Cengiz Dibekoğlu, MD · Last medically reviewed: August 2026 · English patient-education chapter.